EC approves EUSA's dinutuximab beta for high-risk neuroblastoma

EUSA Pharma Ltd. (Hemel Hempstead, U.K.) said the European Commission approved an MAA for dinutuximab beta (APN311) to treat high-risk neuroblastoma in patients ages ≥12 months...